Real World Study of Four PD-1 Agents in China

Real World Study of Immunotherapy-Comparison of Four PD-1 Agents in China

Consecutive patients treated with PD-1 therapy in Qingdao City were included in our study. The effecy and safety of the four PD-1 agents according to clinical outcomes in real world will be studied.

Consecutive patients treated with PD-1 therapy in Qingdao City were included in our study. The effecy and safety of the four PD-1 agents according to clinical outcomes in real world will be studied. ORR will be studied of the four PD-1 agents（nivolumab, pembrolizumab, toripalimab, sintilimab）

Inclusion Criteria:

• Patients with lung cancer, liver cancer and other solid cancers
• Histologically or cytologically confirmed diagnosis cancer treated with PD-1 agents
• At least one measurable lesion
• Eastern Cooperative Oncology Group (ECOG) Performance Scale 0 or 1 Adequate organ function

Exclusion Criteria:

• patients treated with PD-1 agents less than 2 terms